Parkinson’s disease is a chronic disease that requires long-term treatment. Among the drugs used to treat Parkinson’s disease, compound dopa preparations such as methyldopa and restorative dopa are the most effective; however, many patients are afraid to take such drugs because they are concerned about possible adverse effects such as motor fluctuations and allodynia after taking compound dopa preparations. Scientific studies have found that compounded dopa preparations at reasonable doses can effectively improve symptoms without significantly increasing the risk of adverse reactions. In the past, the dose of dopamine was determined primarily based on experience or patient perception, which could result in a significant underdose resulting in a lack of efficacy, or a relatively high dose in the pursuit of significant improvement. Based on our team’s findings, a standardized levodopa efficacy review by physicians is expected to screen for the lowest possible dose of the drug that is effective in improving symptoms. This is easy, possible, inexpensive, and requires only one to several days of hospitalization (typically no more than five days), and may allow for the evaluation of a clear improvement in symptoms and thus the accuracy of the diagnosis, as well as the accurate evaluation of the appropriate dose and frequency of dosing.